Scientist.com Announces Launch of Research Marketplace for BIAL
Scientist.com, the biopharma industry’s leading R&D platform, today announced the launch of a private online marketplace for BIAL. The partnership will connect BIAL researchers with over 4,000 pre-signed service providers available on Scientist.com’s digital platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005035/en/
"As a leading Neuroscience R&D pharmaceutical company, we understand the importance of having reliable access to information, efficient processes and the right resources. That is why we are excited to partner with Scientist.com to streamline our R&D efforts and connect with the best scientific research partners and solution providers,” said Joerg Holenz, General Manager of BIAL R&D. “With this partnership, we can better focus on what matters most: delivering innovative solutions to cure diseases."
BIAL is an R&D focused pharmaceutical company that is headquartered in Portugal and has operations in various locations around the world, notably in the most competitive European pharmaceutical markets. The company is committed to discovering, developing and bringing to market innovative medicines. BIAL's main focus is on two therapeutic areas: Parkinson's Disease, which affects more than 10 million people globally, and epilepsy, which impacts over 50 million people worldwide.
"At Scientist.com, we are committed to supporting companies like BIAL that are dedicated to improving the lives of people living with neurological diseases. BIAL's innovative medications are making a real impact on a global scale, and we are proud to partner with them and support their commitment to discovering and developing new treatments in the neurosciences. Together, we can make a difference in the lives of those who need it most,” said Kevin Lustig, PhD, CEO and Founder of Scientist.com.
Scientist.com currently operates award-winning research marketplaces for 24 of the world’s top 30 pharmaceutical companies, over 100 biotech companies and the National Institutes of Health (NIH). The company’s Science as a Service® platform digitizes a company’s entire research operations, enabling researchers to focus more of their time on experimental design and results analysis. Scientist.com helps researchers outsource everything but the genius.
About BIAL
BIAL is an innovation-driven pharmaceutical company aiming to improve people’s lives worldwide. With 98 years of experience, BIAL is strongly committed to therapeutic innovation, consistently investing over 20% of its annual turnover in R&D, being neurosciences its major area of research. Based on its own innovative medicines and with a consistent partnering program, BIAL has extended its presence worldwide. The company has ten affiliates in three different continents – Europe, America and Africa – and its products are present in fifty countries, fulfilling its purpose of making a real difference in the lives of people all over the world.
For more information about BIAL, please visit www.bial.com.
About Scientist.com
Scientist.com's mission is to empower and connect scientists worldwide. The company's digital research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world's top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world's largest network of scientific suppliers.
Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005035/en/
Contact information
Sean Preci
marketing@scientist.com
+1 858-815-9274
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WEF Special Meeting Concludes in Riyadh With World Leaders Calling for Clear, Irreversible Path to Peace and Prosperity as Top Global Priority30.4.2024 00:02:00 EEST | Press release
Riyadh hosted more than 1,000 global leaders for the two-day World Economic Forum (WEF) Special Meeting in Riyadh, where leading political, economics, energy and technology figures called for clear pathways to stability, prosperity and inclusive growth opportunities in the face of rising cross-border challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429767765/en/ Saudi Minister of Economy and Planning His Excellency Faisal Alibrahim announces Saudi Arabia will join the AI Governance Alliance to co-launch the ‘Inclusive AI Initiative for Growth and Development’ (Photo: AETOSWire) The more than 1,000 participants in for the WEF Special Meeting on Global Collaboration, Growth and Energy for Development made it the highest-ever number of registrations for a WEF event hosted outside of its Annual Meeting venue in Davos Klosters, Switzerland. The Special Meeting set the stage for the launch of several initiatives in th
CORRECTING and REPLACING ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology30.4.2024 00:00:00 EEST | Press release
Please replace the release dated April 26, 2024 with the following corrected version due to multiple revisions. The updated release reads: RENAGADE THERAPEUTICS CONTINUES COMMITMENT TO GANNA BIO AND GLYCAN BIOLOGY GanNA founders include Carolyn Bertozzi, Ph.D., Richard D. Cummings, Ph.D., Ryan A. Flynn, M.D., Ph.D., and Namita Bisaria, Ph.D., M.B.A. Additional investment strengthens ReNAgade’s delivery platform with unique conjugation platform based on novel glycobiology ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines, today announced its ongoing commitment to unlock the potential of glycobiology through support for ongoing research at GanNA Bio, and an integration of the key founders of GanNA Bio into the ReNAgade ecosystem. GanNA Bio was formed in 2021 and invested in by ReNAgade to harness novel glycobiology to enable extra-hepatic RNA delivery based on pioneering research licensed from Stanford University, Boston Children’s Hospital, and Beth Is
Sun Nuclear Announces Landmark Update to Further Advance Radiation Therapy Workflows29.4.2024 23:30:00 EEST | Press release
Sun Nuclear, a Mirion Medical company, today announced the upcoming version 5.0 release of its SunCHECK® software for comprehensive Quality Management in radiation therapy. The SunCHECK software is used globally by radiation therapy departments to manage delivery system oversight and patient-specific treatment quality --- all in one platform. SunCHECK Version 5.0 introduces a broad range of features and user-driven enhancements that optimize workflows and prioritize patient safety. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429991805/en/ Sun Nuclear, a Mirion Medical company, announced the upcoming version 5.0 release of its SunCHECK® software for comprehensive Quality Management in radiation therapy. SunCHECK v5.0 addresses clinical workflow challenges with new treatment plan assessment capabilities, enhanced TPS/OIS integration, expanded QA device control, and worklist-based UI. (Graphic: Business Wire) The Connecte
Hologic to Acquire Endomagnetics Ltd, a Breast Surgical Guidance Company29.4.2024 23:05:00 EEST | Press release
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced that it signed a definitive agreement to acquire Endomagnetics Ltd (Endomag®), a privately held developer of breast cancer surgery technologies, for approximately $310 million, subject to working capital and other customary closing adjustments. “Endomag’s suite of solutions complements our existing breast surgery portfolio and will provide surgeons and radiologists with an expanded range of options to meet the individual needs of more patients undergoing critical breast cancer procedures,” said Erik Anderson, President of Breast and Skeletal Health Solutions at Hologic. “With a global footprint and a similar commitment to women’s health, we are excited about the potential of welcoming the Endomag team and our future opportunities together to increase access to these technologies and better serve patients across the breast health continuum of care.” Endomag, which is based in Cambridge, United Kingdom, deve
PsiQuantum to Build World’s First Utility-Scale, Fault-Tolerant Quantum Computer in Australia29.4.2024 23:00:00 EEST | Press release
PsiQuantum today announced it will build the world’s first utility-scale quantum computer at a strategically located site near Brisbane Airport in Brisbane, Australia. The Australian Commonwealth and Queensland Governments will invest $940M AUD ($620M USD) into PsiQuantum through a financial package, comprised of equity, grants, and loans. PsiQuantum is on an aggressive plan to have the site operational by the end of 2027. A fault-tolerant quantum computer will be able to solve commercially useful problems across industries built upon chemistry, math, and physics; thereby transforming critical industries – including renewable energy, minerals and metals, healthcare and transportation – that will propel the global economy for decades to come. The quantum computing industry has long faced complicated scaling challenges in building a quantum computer with enough physical qubits to enable error-correction, making it capable of delivering on quantum computing’s promise. PsiQuantum has scale
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom